Kasauli’s Central Research Institute (CRI) etched a new chapter in India’s vaccine journey with the launch of its first indigenous Tetanus and Adult Diphtheria (TD) vaccine, officiated by Union Health Minister JP Nadda. Held on February 21, the event underscores a pivotal step toward healthcare independence amid growing global demands for reliable immunizations.
Nadda described the initiative as a ‘game-changer’ for public health, spotlighting CRI’s breakthrough in domestic production. He commended the institute’s scientists for delivering a vaccine that aligns with national self-reliance goals, boosting immunization rates to 99 percent—a feat celebrated worldwide.
Under the Universal Immunization Programme, CRI pledges 55 lakh doses by April 2026, with plans to scale up output steadily. This commitment reflects coordinated state-level efforts inspired by PM Modi’s vision for self-sufficient health infrastructure.
Reflecting on India’s pharmaceutical legacy, Nadda noted its status as the global pharmacy and third-place WHO ranking in vaccine regulation. He highlighted the stark contrast between past vaccine timelines—30 years for TB drugs, decades for tetanus—and the COVID-19 era’s speed: two vaccines in nine months, over 2.2 billion doses delivered digitally.
The TD vaccine’s introduction fortifies defenses against preventable diseases, particularly for adults. As India accelerates production, it positions itself as a beacon of innovation, ensuring equitable access to life-saving vaccines and inspiring emerging vaccine producers globally.